Cytek Biosciences, Inc.
CTKB
$3.96
$0.195.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 44.14M | 62.14M | 52.29M | 45.60M | 41.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.14M | 62.14M | 52.29M | 45.60M | 41.46M |
| Cost of Revenue | 22.88M | 29.26M | 24.74M | 21.74M | 21.30M |
| Gross Profit | 21.25M | 32.89M | 27.55M | 23.87M | 20.16M |
| SG&A Expenses | 30.11M | 29.52M | 27.79M | 25.67M | 25.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.60M | 67.74M | 61.49M | 56.23M | 56.43M |
| Operating Income | -18.46M | -5.59M | -9.19M | -10.62M | -14.98M |
| Income Before Tax | -17.37M | -4.03M | -7.77M | -6.78M | -11.27M |
| Income Tax Expenses | 1.49M | 40.05M | -2.29M | -1.19M | 136.00K |
| Earnings from Continuing Operations | -18.87M | -44.08M | -5.48M | -5.58M | -11.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.87M | -44.08M | -5.48M | -5.58M | -11.40M |
| EBIT | -18.46M | -5.59M | -9.19M | -10.62M | -14.98M |
| EBITDA | -16.60M | -3.70M | -7.27M | -8.73M | -13.10M |
| EPS Basic | -0.15 | -0.34 | -0.04 | -0.04 | -0.09 |
| Normalized Basic EPS | -0.08 | -0.02 | -0.04 | -0.03 | -0.05 |
| EPS Diluted | -0.15 | -0.34 | -0.04 | -0.04 | -0.09 |
| Normalized Diluted EPS | -0.08 | -0.02 | -0.04 | -0.03 | -0.05 |
| Average Basic Shares Outstanding | 128.70M | 128.17M | 127.55M | 126.93M | 128.34M |
| Average Diluted Shares Outstanding | 128.70M | 128.17M | 127.55M | 126.93M | 128.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |